Disse effekter var relateret til de øgede serumprolaktinniveauer, der skyldes risperidons dopamin D2- receptorblokerende aktivitet.
These effects were related to the increased serum prolactin levels, resulting from the dopamine D2-receptor blocking activity of risperidone.